Cubist Pharmaceuticals Completes Acquisition of Adolor

Cubist Pharmaceuticals has completed the acquisition of Adolor Corporation for an aggregate upfront cash consideration of approximately $221 million.

Cubist Pharmaceuticals, Inc. said Monday that it has completed the acquisition of Adolor Corporation for an aggregate upfront cash consideration of approximately $221 million.

All outstanding shares of Adolor were acquired for $4.25 per share in upfront cash plus one Contingent Payment Right (CPR) per share, entitling the holder to receive additional cash payments of up to $4.50 for each share owned if certain regulatory approvals and/or commercialization milestones for ADL5945 are achieved.

"We are pleased to have completed the acquisition of Adolor, and our team is excited to begin marketing ENTEREG alongside CUBICIN and DIFICID, while continuing the development of ADL5945 together with our other promising late-stage candidates,” said Cubist President and Chi